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Stromal-epithelial interactions dictate cancer progression and
therapeutic response. Prostate cancer (PCa) cells were identified
to secrete greater concentration of mitochondrial DNA (mtDNA)
compared to noncancer epithelia. Based on the recognized coevolu-
tion of cancer-associated fibroblasts (CAF) with tumor progression,
we tested the role of cancer-derived mtDNA in a mechanism of
paracrine signaling. We found that prostatic CAF expressed DEC205,
which was not expressed by normal tissue-associated fibroblasts.
DEC205 is a transmembrane protein that bound mtDNA and contrib-
uted to pattern recognition by Toll-like receptor 9 (TLR9). Comple-
ment C3 was the dominant gene targeted by TLR9-induced NF-κB
signaling in CAF. The subsequent maturation complement C3 matu-
ration to anaphylatoxin C3a was dependent on PCa epithelial inhi-
bition of catalase in CAF. In a syngeneic tissue recombination model
of PCa and associated fibroblast, the antagonism of the C3a receptor
and the fibroblastic knockout of TLR9 similarly resulted in immune
suppression with a significant reduction in tumor progression, com-
pared to saline-treated tumors associated with wild-type prostatic
fibroblasts. Interestingly, docetaxel, a common therapy for advanced
PCa, further promoted mtDNA secretion in cultured epithelia, mice,
and PCa patients. The antiapoptotic signaling downstream of ana-
phylatoxin C3a signaling in tumor cells contributed to docetaxel re-
sistance. The inhibition of C3a receptor sensitized PCa epithelia to
docetaxel in a synergistic manner. Tumor models of human PCa
epithelia with CAF expanded similarly in mice in the presence or
absence of docetaxel. The combination therapy of docetaxel and
C3 receptor antagonist disrupted the mtDNA/C3a paracrine loop
and restored docetaxel sensitivity.
prostate cancer | docetaxel | mtDNA | carcinoma-associated fibroblast
Prostate cancer (PCa) is the second leading cause of cancer-related death of men in the United States (1). Stromal-
epithelial interactions define tumor initiation, progression, and
therapeutic resistance (2–6). In the prostate tumor microenvi-
ronment, stromal fibroblasts coevolve with the cancer epithelia
in a reciprocal relationship (7). The central role of cancer-
associated fibroblasts (CAF) was recognized when their absence
was found to result in reduced tumor volumes (8). Conversely, the
combining of nontumorigenic prostatic epithelia with CAF was
found to promote tumorigenesis (9, 10). CAF produce paracrine
growth factors, proteolytic enzymes, and components of the ex-
tracellular matrix, apparently in response to cues from tumor cells
(11–14). Prostatic fibroblasts contribute to the androgen signaling
axis in prostate development, and CAF are attributed to the
development of castrate resistance (2, 3, 15, 16). Paracrine
protumorigenic signaling between CAF and the cancer epithelia
in contrast to normal tissue-associated fibroblasts (NAF) seems
to be a durable result of epigenetic programming in some cases
that are able to promote tumor growth (7, 17, 18). However, the
mechanisms regulating this cross talk are not well elucidated in
the context of chemotherapy. The goal of this study was to better
understand how docetaxel treatment, a mainstay for PCa patients
with advanced disease, impacts CAF and its role in supporting
tumor expansion.
Taxanes, inclusive of docetaxel, paclitaxel, and cabazataxel,
hyperstabilize microtubules to inhibit intracellular trafficking and
signaling, cause mitotic arrest, and induce apoptotic cell death for
numerous solid tumor types, inclusive of ovarian, breast, lung,
head and neck, and prostate (19). Docetaxel was the first taxane
to provide an overall survival benefit for men with metastatic,
castrate-resistant prostate cancer (20). Phase 2 studies have tested
the use of taxanes, prior to androgen-targeted therapy failure, and
demonstrated positive biochemical tumor response (21, 22). Signif-
icantly, the combined use of hormone therapy and docetaxel for
castrate-sensitive PCa patients with high-volume localized and
metastatic disease provided a significant survival advantage com-
pared to castration therapy alone in two independent randomized
trials (23, 24). Despite the importance of taxanes in the management
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of PCa, its utility is limited by toxicity and acquisition of chemo-
resistance. Here, we examine the role of the PCa microenvironment
in docetaxel chemoresistance.
There is a large body of evidence describing the role of mi-
tochondrial DNA (mtDNA) in PCa (25–27). Proteins in mito-
chondrial complexes I, III, IV, and V involved in oxidative
phosphorylation are encoded by mtDNA. Mutations found in
mtDNA increase tumorigenicity in PCa and deregulated mito-
chondrial metabolism is known to promote prostate carcino-
genesis (26, 28). PCa cells have greater mitochondrial content
than benign prostate epithelium, and alterations in mtDNA copy
number may reflect disruption of the normal prostate glandular
architecture (29, 30). Furthermore, mtDNA instability is a hall-
mark of human cancers (31). PCa patients are found to have
measurable concentrations of mtDNA in serum (32). In this
study, we tested the hypothesis that secreted mtDNA functions
as a mediator of epithelia-CAF cross talk. We reasoned that the
mtDNA could potentially signal adjacent cells through pattern
recognition receptors, such as toll-like receptor 9 (TLR9). Many
similar pattern recognition receptors are recognized on the
surface of immune cells for the defense from bacterial and viral
infection. TLR4 is reported to be expressed in skin and lung
fibroblasts (33, 34). Recently, we reported the expression of
TLR2 and TLR4 activity in gingival fibroblastic cells (35).
However, endosomal TLR9 is described in macrophage and
dendritic cells signal in response to unmethylated bacterial DNA
for the initiation of an inflammasome signaling cascade associ-
ated with IL-1β and IL-6 expression (36). We identified a re-
ciprocal signaling cascade initiated by PCa epithelia-derived
mtDNA signaling to CAF via TLR9 activity in potentiating a
downstream paracrine response on PCa epithelia.
Results
Activation of TLR9 and Anaphylatoxin C3a in Cancer-Associated
Fibroblast through Mitochondrial DNA. Based on reported elevation
of mtDNA in PCa patient blood (32), we measured the mtDNA
content in the conditioned media of prostate cell lines. We found
that PCa lines (PC3, LNCaP, and TRAMPC2) expressed 3 to
10 times more mtDNA in the conditioned media than a benign
prostate epithelial cell line, BPH1 (Fig. 1A). To determine if there
was a paracrine impact of mtDNA signaling in CAF, we incubated
CAF cells with conditioned media from LNCaP (LNCaP-CM) for
the expression of the mtDNA cognate receptor TLR9 and its
downstream effectors. TLR9 messenger RNA (mRNA) expres-
sion was found to be significantly up-regulated by LNCaP-CM in
CAF, compared to NAF or treatment of either CAF/NAF with
BPH1-CM (SI Appendix, Fig. S1A). Examining the DNA content
of the LNCaP-CM, we found that the amount of mtDNA was
∼10-fold greater than telomeric DNA (SI Appendix, Fig. S1B).
PCa epithelial conditioned media treatment of CAF resulted in
up-regulation of TLR9 and downstream phosphorylated TAK1,
NF-κB p65 phosphorylation, cleaved-caspase1, and IL-1β protein
expression (Fig. 1B and SI Appendix, Fig. S1C). As exosome-
mediated transfer of mtDNA was a possibility, we treated CAF
cells with ultracentrifuge-enriched exosomes generated by LNCaP
cells as well as exosome-depleted LNCaP-CM. We found that the
exosome-depleted LNCaP-CM induced TAK1, NF-κB signaling,
and C3a expression in CAF, comparable to unaltered LNCaP-CM
(SI Appendix, Fig. S1D). However, the exosome-enriched fresh
media did not seem to induce the same signaling axis. This finding
was corroborated by inhibiting exosome generation, as the LNCaP
cells with the dynamin inhibitor, dynasore (37), showed no ap-
preciable changes in mtDNA content in the media (SI Appendix,
Fig. 1. Activation of TLR9 and C3a by mtDNA. (A) mtDNA was measured from conditioned medium (CM) of prostatic epithelia after 48 h of incubation (n =
3). (B) Protein expression in CAF treated with LNCaP-CM was visualized by Western blot. (C) DEC205 expression was measured in NAF and CAF treated with
LNCaP-CM by Western blot. (D) DEC205 was immunoprecipitated, cross-linked, and subjected to mtDNA PCR amplification for MT-CO2 following CAF in-
cubation with fresh RPMI or LNCaP-CM. CAF cell lysate prior to immunoprecipitation or IgG immunoprecipitant was used as total input and negative controls,
respectively. (E) mRNA expression profiles of the NF-κB–signaling targets in CAF incubated with LNCaP-CM were compared to control-CM in the heat map (n =
4). (F) Volcano plot showing distribution of differential mRNA expression levels in CAF and CAF incubated with LNCaP-CM. While only secreted proteins were
illustrated in the heat map, all 84 NF-κB target genes were represented in the volcano plot. (G) TLR9 and anaphylatoxin C3a protein expression was visualized
in CAF incubated with LNCaP-CM incubated with or without DNase1 treatment. DNase activity was heat inactivated after 10 min. (H) MtDNA secreted by PCa
epithelia signal CAF by binding DEC205 and subsequent TLR9-mediated anaphylatoxin C3a expression. *P < 0.05, **P < 0.01.
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Fig. S1E). Since TLR9 is a cytoplasmic receptor, we sought to
identify a mediator for DNA entry into the cell. Candidate me-
diators with the capacity to bind DNA, such as HMGB1, HMGA2,
and DEC205, were found to be expressed by CAF in response to
LNCaP-CM (SI Appendix, Fig. S1F). HMGB1 expression, previously
associated Toll like receptor signaling, was similarly induced by
both NAF and CAF cells in response to LNCaP-CM.
HMGA2 expression, demonstrated to promote cell proliferation,
was constitutively expressed regardless of LNCaP-CM treatment.
However, LNCaP-CM induced DEC205 protein expression in
CAF, but not NAF (Fig. 1C). DEC205 (LY75) is a transmembrane
endocytic receptor reported to bind and internalize unmethylated
CpG by dendritic cells (38). Due to its differential expression in
CAF and NAF cells, the binding capacity of DEC205 to mtDNA
was tested in CAF through an adaptation of chromatin immuno-
precipitation, termed mtDNA immune precipitation (mDIP). The
mitochondrial MT-CO2 gene was PCR amplified following im-
munoprecipitation of DEC205 in the presence of LNCaP-CM, but
not in its absence (Fig. 1D). Following discovery that NF-κB sig-
naling in CAF was a result of PCa-derived mtDNA, we performed
a focused qPCR array to determine the effect of NF-κB on
downstream target genes. As expected, LNCaP-CM induced the
expression of multiple inflammatory cytokines by CAF, including
IL-6, CXCL8, and CCL11 (Fig. 1E). Interestingly, complement
C3 was upregulated by >12 Log2-fold with LNCaP-CM over con-
trol, the greatest differentially expressed gene in CAF cells (Fig.
1F). The role of complement C3 action is central to the innate
immune response to bacterial and viral infection. C3 has also been
implicated in potentiating tumor cell growth (39). However, the
active component, anaphylatoxin C3a, is a product of a tightly
regulated proteolytic cleavage of C3 (40). Interestingly, we
found that LNCaP-CM–induced TLR9 and C3a expression by
CAF was sensitive to DNase treatment (Fig. 1G). Thus, mtDNA
secreted by PCa epithelia can bind DEC205 on the cell surface of
CAF and activate TLR9 and C3a maturation (Fig. 1H).
To explore the role of TLR9 in C3a expression, prostatic fi-
broblasts from wild-type and TLR9-knockout mice were treated
with CpG oligonucleotides, ODN 1826 (synthetic ligand for
TLR9, CpG-ODN), or LNCaP-CM. TLR9 and phosphorylated
TAK1 was up-regulated by CpG-ODN (Fig. 2A). Further up-
regulation of TLR9 and TAK1 was observed with incubation
with LNCaP-CM. DNase1 treatment of LNCaP-CM reduced
TLR9 protein expression as well as C3a expression by wild-type
mouse fibroblasts. TAK1 phosphorylation and anaphylatoxin
C3a expression by LNCaP-CM was found to be dependent on
TLR9 expression. However, treating the wild-type prostatic fi-
broblasts with CpG-ODN generated dramatically less anaphy-
latoxin C3a compared to treatment with LNCaP-CM, similar to
that found when LNCaP-CM was treated with DNase1. Enzyme-
linked immunosorbent assay (ELISA)-based quantitation of C3a
secretion by CAF corroborated expression when incubated with
TRAMPC2-CM or LNCaP-CM, but negligible expression when
incubated with CpG-ODN (Fig. 2B). These results show that PCa
epithelial secretion of mtDNA could promote TLR9 signaling and
anaphylatoxin C3a expression by CAF, whereas CpG alone could
activate TLR9 but was not sufficient for C3 protein maturation.
Complement processing can occur through an enzymatic acti-
vation cascade or alternative pathways culminating in the cleavage
of complement C3 (41). Cleavage products of C3 are well described
for microbe opsonization and activation of proinflammatory sig-
naling. As the classical pathway involves the complex of comple-
ment proteins C1b and C2b for C3 cleavage, this was not a likely
mechanism in cultured fibroblasts. Therefore, the alternative
pathway involving reactive oxygen-mediated cleavage was tested
(42). Not surprisingly, the treatment of CAF with LNCaP-CM
resulted in reactive oxygen generation, as revealed by 2′,7′-
dichlorofluorescin diacetate (DCFDA) fluorescent signal using
fluorescence-activated cell sorting (FACS) analysis and visualized
by fluorescent microscopy (Fig. 2 C and D). CpG-ODN treatment
promoted no such reactive oxygen signal and N-acetylcysteine
Fig. 2. Mechanism of C3a generation by CAF. (A) TLR9 signaling was tested in mouse prostatic fibroblasts from cultured wild type (WT) or TLR9-knockout
(TLR9−/−) mice treated with CpG-ODN or LNCaP-CM in the presence and absence of DNase1 treatment. (B) Secreted C3a was measured by ELISA from CAF and
NAF conditioned media following treatment with CpG-ODN, LNCaP-CM, or TRAMPC2-CM (n = 3). (C) Flow cytometry was used to quantitate intracellular
reactive oxygen by DCFDA fluorescence in CAF incubated with control, CpG-ODN, or LNCaP-CM DCFDA+ cells, absent the dead cell marker (7-amino-
actinomycin D), were quantitated. (D) Cytoplasmic green DCFDA was localized with DAPI nuclear counter stain by fluorescence microscopy. (Scale bar, 16 μm.)
(E) Catalase activity was quantitated in CAF following incubation with fresh media (control), CpG-ODN, or LNCaP-CM. (F) Protein expression of complement
C3 and anaphylatoxin C3a in CAF was Western blotted. The CAF were incubated with either CpG-ODN in the presence and absence of the catalase inhibitor 3-
amino-1,2,4-triazole (3AT) or LNCaP-CM in the presence or absence of reactive oxygen inhibitor N-acetyl cysteine (NAC). (G) mtDNA from in LNCaP-CM binds
DEC205 for internalization in CAF cells for subsequent TLR9 signaling. LNCaP-CM inhibition of catalase activity allows ROS accumulation to facilitate C3a
maturation in the CAF. *P < 0.05, **P < 0.01, ***P < 0.001, and ns, not significant.
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(used as a reactive oxygen inhibitor) suppressed LNCaP-CM–in-
duced reactive oxygen as well as anaphylatoxin C3a maturation. As
catalase can mitigate the reactive oxygen content of cells, its activity
was measured in CAF. We found that catalase activity in CAF was
significantly suppressed by LNCaP-CM, compared to either un-
treated control or CpG-ODN treatment (Fig. 2E). Western blotting
demonstrated that N-acetylcysteine supplementation blocked the
conversion of C3 to C3a induced by LNCaP-CM (Fig. 2F). How-
ever, the inhibition of catalase by 3-amino-1,2,4-triazole did not
improve anaphylatoxin C3a generation when combined with CpG-
ODN. Ultimately, both CpG-ODN and LNCaP-CM induced
C3 expression in CAF, but anaphylatoxin C3a generation was
dependent on the suppression of catalase activity as well as on
the induction of reactive oxygen by LNCaP-CM (Fig. 2G).
C3a Signaling Enhances PCa Expansion. In an effort to determine a
reciprocal epithelial response to anaphylatoxin C3a expressed by
CAF, we tested the impact of established complement agonists
and antagonists on PCa expansion. We found that LNCaP, PC3,
and TRAMPC2 all expressed the anaphylatoxin C3a receptor
(C3aR, SI Appendix, Fig. S2A). Although HMGB1 was hetero-
geneously expressed by the three epithelial cell lines, negligible
expression of DEC205, TLR9, or C3a reinforced the requirement
of a paracrine TLR9-mediated anaphylatoxin C3a-signaling axis
(SI Appendix, Fig. S2B). Coculturing of CAF and TRAMPC2 cells in
transwells demonstrated that the knockdown of C3aR in TRAMPC2
by small interfering RNA (siRNA) resulted in reduced Ki67+
epithelial proliferative cells, compared to scrambled control siRNA
(SI Appendix, Fig. S2C). Next, the effect of C3a signaling on PCa
cells was tested by incubating LNCaP, PC3, and TRAMPC2 with
an C3aR agonist or scrambled peptide. Agonist peptides to C3aR
were used rather than C3a itself because anaphylatoxins are
extremely labile (43). Exposure of 0.1 μMC3aR agonist for 48 h
increased proliferation, as measured by Ki67 expression, in
LNCaP (28%), PC3 (30%), and TRAMPC2 (21%) compared
to scrambled peptide-treated cells (SI Appendix, Fig. S2D). The
C3aR agonist was further found to promote phosphorylation of
AKT and downstream MAP kinase signaling by phosphoryla-
tion of p42/44 MAPK (p-ERK1/2, Fig. 3A). The up-regulation
of BCL2 was identified as a downstream signaling target of
AKT in support of cell survival.
To validate the observation of C3a signaling, we allografted
mouse prostatic fibroblasts with PCa epithelia into syngeneic C57B/
6 mice. We grafted either wild-type or TLR9-knockout fibroblasts
and recombined them with luciferase-expressing TRAMPC2 cells
under the renal capsule. After the tumors were visible by biolu-
minescent imaging, the mice hosting wild-type prostatic fibroblast
grafts were treated with either vehicle (control) or SB290157, a
C3aR antagonist. Within 3 wk of grafting, the vehicle-treated tu-
mors with wild-type fibroblasts expanded reproducibly; however,
Fig. 3. Role of C3a in PCa progression. (A) PCa cell lines incubated in the absence and presence of C3a receptor agonist peptide (48 h) was Western blotted
for cell survival and proliferation protein expression. (B) C57BL/6 mice were allografted with tissue recombinants of luciferase-expressing TRAMPC2 with wild-
type (wt) or Tlr9−/− fibroblasts. The mice were treated with saline or the TLR9 antagonist SB290157. Luciferase bioluminescence was used to image tumor
progression. (C) Mean tumor volume (mm3) and SD for each treatment condition are depicted (*P < 0.05, n = 8). (D) Immunohistochemistry for phosphor-
ylated AKT, phosphorylated histone-H3, and TUNEL staining of the tumor tissues were performed and quantitated. Hematoxylin was used as a nuclear
counterstain. The corresponding graphs illustrate the mean and SD expression of the staining (n = 4). Statistical significance was determined by one-way
ANOVA (*P < 0.05, **P < 0.01). (E) FACS analysis of the tumor-draining lymph nodes demonstrated that control, C3a antagonist, and TLR9-knockout fi-
broblasts had similar CD3+ T cell infiltration; however, their activation state as determined by CD8+/CD69+ expression differed significantly.
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SB290157 had significantly reduced tumor size (Fig. 3 B and C).
Interestingly, the allografts with TLR9-knockout fibroblasts had
negligible tumor growth, confirming that the role of the associated
paracrine-signaling axis is dependent on TLR9 and C3a. We were
able to perform immunohistochemistry only on the grafts with
wild-type fibroblasts and TRAMPC2 as not enough tissue was
available from grafts with TLR9-knockout fibroblasts. Tumor cell
mitosis, as determined by phosphorylated histone H3 expression, was
significantly lower when the host mice were treated with SB290157
(Fig. 3D). The activation of AKT, localized by phosphorylated AKT
staining, was elevated in the tumor cells allografted with wild-type
fibroblasts and reversed by SB290157 treatment. The C3aR antag-
onist was found to significantly elevate tumor cell death, as localized
by terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining.
Complement anaphylatoxins have a wide spectrum of proin-
flammatory effects. Anaphylatoxin C3a is particularly regarded
for the chemotaxis of myeloid cells and T cells (44–47). We could
not consistently profile the immune infiltrates within the tumor
as tissue was limited in some treatment conditions; therefore, the
draining lymph nodes were evaluated. We observed a similar
reduction of myeloid-derived suppressor cells (CD11b+, Ly6G+)
with SB290157 and TLR9−/− fibroblasts, compared to control saline-
treated mice with TRAMPC2/wild-type fibroblasts (SI Appendix,
Fig. S3). An approximately threefold reduction of M2 macrophage
activation (F4/80+, CD208+, CD69+) was observed in SB290157-
treated mice and TLR9−/− fibroblast-associated tumors, compared
to control by FACS analysis. As T lymphocytes are confirmed
regulators of tumor progression and known to respond to ana-
phylatoxin C3a (48), we measured the impact of C3a antagonism
on T cell recruitment to the tumors. Interestingly, CD3+ T cells on
the whole showed similar recruitment to the tumor-draining lymph
nodes regardless of C3a antagonist or fibroblast TLR9 status (Fig.
3E). However, CD8+ T cell activation, as determined by the ex-
pression of the costimulatory molecule CD69+, was appreciably
down-regulated by C3a antagonist and further down-regulated in
tumors with TLR9-knockout fibroblasts. Under the same condi-
tions, there was little change in Treg (CD3
+, CD4+, CD25+, FoxP3+)
recruitment, but Th17 cell (CD3+, CD4+, CD25+, RORγ+)
recruitment was elevated by SB290157 treatment and TLR9−/− fi-
broblasts (SI Appendix, Fig. S4). However, only half the activated
T helper cells (CD3+, CD4+, CD25+, CD69+) were recruited to
the TLR9−/− fibroblast-associated tumors, compared to either
control or SB290157 treatment. Since functions of T helper cells
include the activation of cytotoxic T cell and macrophage, the di-
minished recruitment of T helper cells in the TLR9−/− fibroblast-
associated tumors could support the reduced activation of cytotoxic
T cells and M2 macrophage activation in these tumors. The further
increase in Th17 (T helper-17) cell recruitment in the SB290157-
treated and TLR9−/− fibroblast-associated tumors support the
general immune-suppressive state of these tumors. Thus, the
resulting changes in tumor size were minimally affected by immune
surveillance and likely driven by the reciprocal tumor epithelial-
fibroblast interaction.
Synergistic Effect of Docetaxel and C3aR Antagonism Inhibit Tumor
Expansion. Based on the observed activation of AKT by ana-
phylatoxin C3a in PCa epithelia, we were curious as to the role of
this prosurvival signal in the context of a mediator of cell death
such as chemotherapy. To determine the clinical relevance of the
TLR9/C3a-signaling axis in PCa patients, we measured plasma
mtDNA content in men within 2 wk prior to treatment and while
undergoing docetaxel treatment (within 4 to 8 wk of start) in a
paired fashion. Docetaxel induced a dramatic increase in circu-
lating mtDNA in the PCa patients (P = 0.006, Fig. 4A). In par-
allel, mice treated with docetaxel (6 mg/kg/wk) for 3 wk showed
significant elevation of plasma mtDNA content (P < 0.05, Fig.
4B). In examining the direct effect of docetaxel on PCa epithelia,
we found docetaxel to profoundly elevate mtDNA secretion by
LNCaP, PC3, and TRAMPC2 cells in a dose-dependent manner
(Fig. 4C). As a control, nontumorigenic BPH1 cells were also
found to secrete more mtDNA in response to docetaxel, but at
levels approximately a tenth of that observed in LNCaP cells (SI
Appendix, Fig. S5A). Incidentally, higher doses of docetaxel were
used for PC3 cells compared to the other two lines due to its
inherent resistance. The influence of stromal-epithelial cross talk
in the development of docetaxel resistance was tested in co-
culture studies within a three-dimensional (3D) matrix of colla-
gen I and Matrigel (4, 18). The coculture of PC3 and CAF
resulted in a doubling of EpCAM+/Ki67+ proliferative epithelia
compared to that when PC3 cells were grown alone (Fig. 4D).
Additional treatment with docetaxel did not appreciably reduce
the CAF-induced proliferative epithelial fraction. The C3aR
antagonist restored the sensitivity of PC3 cells to docetaxel in
coculture. Drug interaction studies reveled that low doses of
SB290157, with little-to-no intrinsic impact on PC3 survival
alone, sensitized the otherwise resistant PC3 cells to docetaxel in
Fig. 4. Docetaxel promotes mtDNA release from PCa cells, and paracrine
TLR9 signaling contributes to therapeutic resistance. (A) Plasma levels of
mtDNA were quantified from PCa patients before and after docetaxel
treatment (n = 9). (B) mtDNA content of plasma from mice treated with
docetaxel was quantitated (n = 3). Data represent the mean ± SD; *P < 0.05.
(C) mtDNA secreted by PCa cell lines treated with docetaxel was elevated in
a dose-dependent manner (n = 3). Significance was determined by repeated
measures ANOVA. (D) Treatment of a 3D coculture model of PC3 and CAF
cells with docetaxel and the TLR9 antagonist SB290157 supported differ-
ential epithelial proliferation as determined by quantitating EPCaM+/Ki-67
+
cells by FACS analysis (n = 3). (E) Synergistic cooperativity was identified in
PC3 cell viability measured by MTT assay following treatment with docetaxel
and SB290157 through the Chou-Talalay method (n = 4). Values below the
confidence interval (CI) of 1 are considered a synergistic combination.
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a synergistic manner (fractional inhibitory concentration index <0.5;
Fig. 4E and SI Appendix, Fig. S5B).
The therapeutic significance of the observed stromal-epithelial
cross talk was tested in male nude mice with tissue recombinant
xenografts of CAF and PC3 cells. Tumor growth curves indicated
that tumor volume was not significantly reduced by treatment
with the low dose of docetaxel (6 mg/kg/wk) alone, compared to
vehicle treatment (Fig. 5A). However, the combined treatment
of docetaxel and SB290157 significantly limited tumor growth
(P < 0.05). No significant impact on the body weight was ob-
served in any treatment groups, which supports a low-dose tax-
ane therapy strategy with reduced toxicity (SI Appendix, Fig.
S5C). Western blotting of the tumor tissues revealed the acti-
vation of TAK1, AKT, and ERK1/2 in docetaxel-treated mice
compared to vehicle treatment (Fig. 5B). The up-regulation of
plasma mtDNA in docetaxel-treated mice supported the ele-
vated phosphorylation of TAK. SB290157 treatment reduced
AKT and ERK1/2 phosphorylation induced by docetaxel. Im-
portantly, BLC2 was reduced by the combination therapy. His-
tology of the tumors and immunohistochemistry of the corresponding
tissues allowed us to localize and quantitate the relevant signaling
molecules (Fig. 5C and SI Appendix, Fig. S5D). The significant
docetaxel induction of phosphorylated TAK1, C3, and TUNEL
staining was not significantly altered by C3 antagonism. However,
docetaxel-treatment–induced AKT phosphorylation was dimin-
ished by SB290157 treatment. In parallel, docetaxel reduced
mitosis, indicated by phosphorylated histone-H3 localization, that
was further down-regulated by SB290157 treatment. Combining
low doses of docetaxel with C3aR antagonism ultimately limited
tumor growth.
Discussion
Our data show that reciprocal paracrine signaling between PCa
and associated fibroblasts promotes cancer progression and
facilitates docetaxel resistance. We hypothesized that mtDNA
could be the paracrine-signaling molecule generated by PCa cells
(Fig. 6). The docetaxel-induced mtDNA secretion from PCa cells
into the tumor microenvironment was significantly greater than
Fig. 5. Synergistic effect of docetaxel and SB 290157 inhibits tumor growth. (A) Subcutaneous xenografts of PC3 and CAF tumor volumes were longitudinally
measured. When tumor average volume reached 80 mm3, mice were treated with vehicle or docetaxel in the presence or absence of SB290157 for 20 d (n = 4).
Representative images show each group of mice (Inset). (B) Western blots of the tumor tissues for the respective treatments are shown with the mean
quantitation for each condition displayed below (n = 3). (C) Immunolocalization of phosphorylated TAK1, complement C3, phosphorylated AKT, phos-
phorylated histone H3, and TUNEL expression in tumor tissues (brown) was counterstained with hematoxylin (blue). The corresponding graphs illustrate the
mean and SD expression of the respective staining (n = 5). Arrowheads indicate positive staining. Statistical significance was determined by one-way ANOVA
(*P < 0.05, **P < 0.01). ns, no statistical significance.
8520 | www.pnas.org/cgi/doi/10.1073/pnas.1910952117 Haldar et al.
the basal levels of mtDNA secreted by PCa cells. Accordingly,
prostate tumors in both murine models and men harboring
prostate tumors demonstrated elevated circulating mtDNA when
treated with docetaxel. For subsequent CAF signaling, the mtDNA
required entry into the cytoplasm for TLR9 activation. Based on the
previous demonstration of DEC205 capture of CpG in dendritic
cells (38), a similar scenario was explored for the prostatic CAF.
Instead of unmethylated bacterial DNA, we demonstrated that, in
fact, DEC105 could directly bind mtDNA on CAF cells for classic
pattern recognition receptor TLR9 activation of TAK1 and NF-κB
(49). TLR9 was identified to be essential for complement C3 ex-
pression by CAF in response to mtDNA, but the accumulation of
reactive oxygen driving C3 cleavage and anaphylatoxin C3a
generation was dependent on PCa epithelial interaction. Re-
leased anaphylatoxin C3a in the tumor microenvironment in-
creased proliferation of cancer cells and potentiated resistance
to docetaxel treatment.
It is apparent that PCa-induced paracrine NF-κB activation in
CAF dramatically potentiated complement C3 expression over
other known NF-κB targets (Fig. 1). There is a well-described
immune defense for bacterial pathogens that includes Toll-like
receptor-mediated complement expression and generation of ana-
phylatoxins (50). However, the novel mechanism of TLR9 induction
by PCa-derived mtDNA paracrine signal transduction mechanism
in CAF cells was not observed by NAF cells (Fig. 1). Cell-free
circulating mtDNA release in plasma at low levels under cellular
stress is reported in instances of cancer, trauma, infections, stroke,
and autoimmune, metabolic, and rheumatic diseases (51, 52).
While activated T cells can signal dendritic cells through exosome-
based delivery of mtDNA (53), this was not necessarily the means
of paracrine communication between PCa and CAF. Exosome
depletion of LNCaP-CM and dynamin inhibition LNCaP cells had
little effect on TAK1 and C3a expression by CAF (SI Appendix,
Fig. S1). Uniquely, DEC205 was expressed by CAF in the context
of PCa epithelial-conditioned media for endocytic delivery of
mtDNA and TLR9 activation. Docetaxel further potentiated PCa
release of mtDNA by over threefold in multiple cell lines (Figs. 1
and 4). The expression of TLR9 and C3a was similarly induced
by LNCaP-CM by human CAF and wild-type mouse prostatic
fibroblasts (Figs. 1 and 2). The activation of the complement sys-
tem in response to pathogens involves three major pathways: 1) the
classical pathway, via antigen-antibody complexes; 2) the lectin
pathway, via binding of pattern-recognizing mannose-binding lec-
tins; and 3) the alternative pathway, via any permissive microbe
surfaces (41). In all three complement activation pathways, the
C3 convertase complex cleaves C3 molecules to form anaphyla-
toxin C3a. Yet another mechanism of C3 conversion identified in
neutrophils involving hydrogen peroxide-related oxygen radicals,
such as hypochlorite (42), was the mechanism considered for the
stromal-epithelial signaling axis. We found catalase inhibition in
CAF to be essential for reactive oxygen species (ROS) accumula-
tion and maturation of anaphylatoxin C3a (Fig. 2). These findings
supported the absence of C3 cleavage in CpG-ODN–treated CAF
cells despite NF-κB activation.
Our findings provide a paradigm in which the activation of
complement by CAF was distinct from its immunogenic role in
promoting tumor growth. Complement proteins can indirectly
affect cancer growth by their impact on the host’s innate immune
response to the tumor. Antagonizing C3aR signaling with
SB290157 or the fibroblastic knockout of TLR9 significantly
inhibited tumor expansion, all of the while immune cell in-
filtration was found to have shifted to a general immune-
suppressive state (Fig. 3). The reduced recruitment of activated
M2 macrophage and activated T helper cell was associated with
positive recruitment of Th17 cells when TLR9/C3a signaling was
inhibited (SI Appendix, Figs. S3 and S4). These findings reveal
a rational for the observed reduction in activated cytotoxic T cell
recruitment by the C3 antagonist that was further diminished to
nearly one-third of the control tumors with TLR9-knockout fi-
broblasts. In agreement, Wang et al. (54) showed that B16
melanoma growth was slower in C3-deficient mice than in wild-
type mice, which suggests a direct role of anaphylatoxin C3a.
Tumor AKT, ERK1/2, and BCL2 activation/up-regulation was
dependent on fibroblastic TLR9 and epithelial anaphylatoxin re-
ceptor signaling. Knocking down C3aR in TRAMPC2 significantly
reduced its proliferative capacity when cocultured with fibroblasts
(SI Appendix, Fig. S2). The immune-independent C3a activity
acted directly on the tumor cells in a paracrine manner.
Docetaxel resistance is major clinical problem in many cancers
including PCa. Activation of several survival signaling pathways
(e.g., AKT and ERK with BCL2 expression) can promote a re-
sistant phenotype in response to docetaxel treatment. The po-
tential for mtDNA secretion resulting from cell death was ruled
out by parallel apoptosis measurements made with mtDNA
quantitation. Incidentally, when lymphocytes secrete mtDNA in
response to viral infection, it is not associated with cell death
(55). However, since mitophagy is a documented process asso-
ciated with taxane therapy, only fragments of the mitochondrial
genome would likely be found in the media or circulation (56)
with high susceptibility for further degradation. CAF recipro-
cated the PCa-derived mtDNA signal by the TLR9-C3 paracrine
axis to trigger cell proliferation in PCa cells in the context of
docetaxel (Fig. 5). Remarkably, the synergism of docetaxel and
SB290157 was able to sensitize an otherwise resistant PC3 cell
line to reduced docetaxel doses to effectively limit tumor growth.
Better understanding of stromal complement signaling by cancer
cells is needed, as its implications can have a far-reaching impact
on many cancer types currently treated with taxanes. With
docetaxel in clinical trials in combination with immune check-
point inhibition therapy, there is potential for a limited activation
of infiltrating cytotoxic T cells due to the mtDNA/anaphylatoxin
C3a signaling axis. Thus, one must consider the benefits to im-
mune surveillance induced by docetaxel with the tumor-intrinsic
proliferative role of complement signaling.
A final implication of our results is that fibroblast response to
taxane therapy is consequential to cancer epithelial therapeutic
response. Circulating mtDNA has been reported to be a poor
Fig. 6. Illustration of the PCa epithelia and CAF reciprocal interaction. PCa
cells generate mtDNA that can bind DEC205 on the cell surface of CAF.
TLR9 signaling downstream of epithelial-derived mtDNA results in NF-κB–
mediated C3 expression. The accumulation of ROS in CAF facilitated C3a
maturation and paracrine signaling with PCa cells to enable cell survival and
proliferation. Docetaxel treatment of PCa cells results in expanded secretion
of mtDNA in perpetuating C3a expression by CAF further.
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prognostic indicator for PCa patients (32). However, with the
limited number of patients analyzed, we were unable to dem-
onstrate a correlation with the level of mtDNA in circulation
with the length of docetaxel responsiveness. While the epithelial
response to docetaxel can be uncoupled from that of the stromal
fibroblasts, the stromal influence on therapeutic resistance is a
result of paracrine signaling initiated by the PCa epithelia. We
cannot rule out the direct impact of docetaxel on CAF that could
also influence epithelial viability. It should be noted that TLR-
mediated NF-κB signaling is not a phenomenon limited to mammals.
It was originally identified inDrosophila (Toll), with Toll9 involved
in hematopoietic and digestive tract development (57). Although
NF-κB regulation remains conserved, the gene targets are species,
tissue, and cell-type specific; in prostatic CAF, DEC205 expression
was a determinant of NF-κB signaling. The fact that NF-κB ex-
quisitely mediates complement C3 expression by CAF and my-
eloid cells suggests that the hardwiring of this pathway originates
in cells of mesenchymal origin. The mechanism revealed here
demonstrates that tumors can repurpose the pathogen defense
axis for chemotherapy resistance.
Methods
Cell Culture and Animal Experiments. Cultured LNCaP, TRAMPC2, and PC3 (all
from ATCC) were grown in Roswell Park Memorial Institute (RPMI) media
supplemented with 5% fetal bovine serum and treated with docetaxel (Sano-
fiAventis) or SB290157 (1 μM, Calbiochem) for 48 h. Conditioned medium was
treated with DNase1 (0.1 mg/mL, Sigma-Aldrich) in 37 °C for 1 h followed by
heat inactivation. Cultured primary NAF and CAF derived in our laboratory (4)
were treated with LNCaP-CM, CpG-ODN (5 μM, InvivoGen), and N-acetylcys-
teine (10 mM [Sigma-Aldrich]).
Three-dimensional organotypic coculture was performed in a collagen
matrix as previously reported (4). PC3 and CAF were combined in a 1:3 ratio
in collagen matrix contain 50% rat tail collagen I, 20% of Matrigel, 10% of
10× Dulbecco’s Modified Eagle Media (DMEM) and 1× ready DMEM 5%, 1×
ready RPMI 5%, fetal bovine serum 5%, and Nu serum 5%. Cells were
treated with docetaxel and SB290157 for 48 h after 72 h of expansion in the
matrix. The cells were dissociated from the matrix with collagenase and
dispase for Ki67 FACS analysis. FlowJo software (Tree Star Inc.) was used for
FACS analysis.
Male C57BL/6 or Nude mice aged 7 to 8 wk were housed in a pathogen-free
environment at the Cedars-Sinai Medical Center Animal Facility under the
approval of the Institutional Animal Care andUse Committee (# 3679). Subrenal
capsule was performed with wild-type mouse fibroblasts (6 × 105) or TLR9−/−
mouse fibroblasts (6 × 105) combining with mouse prostate epithelial cell
TRAMP-C2 (2 × 105). Treatment with SB290157 (SantaCruz Biotechnology Inc.;
1 mg/kg; [intraperitoneally (i.p.)] daily) was started after 2 wk of grafting in
C57BL/6 mice and continued for 5 wk with longitudinal bioluminescent
monitoring. Subcutaneous xenografts were done by combining PC3 (5 × 105)
and CAF (15 × 105) in Nudemice. Grafts were monitored by caliper throughout
the time course of treatment with docetaxel (6 mg/kg/wk) and SB290157
(1 mg/kg; i.p. daily). All indicated tissues were harvested after 5 wk of treat-
ment were fixed in paraffin embedded for immunohistochemistry or immu-
noblot analysis or dissociated for FACS analysis.
Immunodetection. Paraffin-embedded tissue was processed for immunohis-
tochemical localizationwas performedwith antibodies against p-AKT, p-TAK,
p-histoneH3 (Cell Signaling), C3 (Santa Cruz Biotechnology), and TUNEL
(Thermo Fisher Scientific) as previously described before (58, 59). All of the
slides were scanned using Leica SCN400 (Leica Micro System) and analyzed
by Tissue IA Optimizer (Leica). The values of positively stained cells were
measured in an unbiased manner. C3a concentration of cultured medium
and serum was assayed by sandwich ELISA using a human C3a ELISA kit (BD
Bioscience) according to the manufacturer’s instructions. Western blots
separated by 10, 12, or 15% sodium dodecyl sulfate/polyacrylamide gel
electrophoresis were incubated with primary antibodies for TLR9, DEC205
(LS Bio Seattle), phospho-TAK1, TAK1, phospho-AKT, AKT, phospho-ERK1/2,
ERK, BCL2 (Cell Signaling), and C3 (Santa Cruz Biotechnology). Western blots
were visualized using alkaline phosphatase-conjugated secondary antibodies
(Sigma-Aldrich). The ELISA for anaphylatoxin C3a was performed according to
manufacturer guidelines (LSBio).
DNA Quantitation. Total DNA from serum or cultured medium was isolated by
aQuick-cfDNA Serum and Plasma kit (Zymo Research). The purified DNAwere
PCR amplified by the mitochondria-specific MT-CO2 gene (using the fol-
lowing primers: 5′-CCT GCG ACT CCT TGA CGT TG-3′ and 5′-AGC GGT GAA
AGT GGT TTG GTT-3′). Quantitation was achieved through the use of a
standard curve generated from known purified mtDNA by real time PCR.
Telomere-specific sequence (TTAGGG)14 was measured using the TRAPEZE
RT Telomerase Detection Kit (Millipore).
mDIP. We followed the manufacturer’s chromatin immunoprecipitation
protocol of Zymo-Spin CHIP Kit (Zymo Research). Briefly, mtDNA from con-
ditioned medium was immunoprecipitated either by normal rabbit IgG an-
tibodies as a negative control or by anti-DEC205 antibody (Santa Cruz
Biotechnology). A total of 100 ng of mitochondrial DNA was added to
condition medium as a positive control. Nonimmunoprecipitated DNA was
used as total input control. The purified immunoprecipitated DNA was PCR
amplified by mitochondria-specific primers (MT-CO2) as mentioned above
and was compared to input DNA.
Detection of Reactive Oxygen Species. FACS and fluorescent staining was
performed for ROS detection in CAF by using DCFDA (Sigma-Aldrich). Cells
were labeled with 10 μM H2-DCFDA for 30 min at 37 °C in the dark, and ROS
production was monitored under fluorescence microscopy and quantified
through flow cytometric analysis.
Catalase Activity Assay. Catalase activity was measured in CAF lysate by using
a OxiSelect Catalase Activity Assay Kit (Cell Biolabs, San Diego) according to
the manufacturer’s protocol, and absorbance was taken at 520 nm in a 96-
well plate. Ten millimolar of 3-amino-1,2,4-triazole (Santa Cruz Biotechnology)
was used as a catalase inhibitor.
Statistical Analysis. Experiments were done aminimum of three times. Results
are shown in terms of mean ± SD. Student’s t test and one-way ANOVA were
used for comparisons among groups, and repeated measured ANOVA was
applied for determining the significance of two or more data series. Statis-
tical tests using Origin software (OriginLab), are reported in the figure
legends, along with the associated P values. Cell viability was examined
using MTT assay as indicated by the manufacturer (Thermo Fisher); for the
calculation of synergistic drug interactions, the Chou-Talalay method was
performed (R Package).
Data Availability Statement.All data discussed in the paper are available in the
main text and SI Appendix.
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